Aspacytarabine Drug Asset Due Diligence Report 2026

This Aspacytarabine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Aspacytarabine can convert its Small molecule drug profile and DNA polymerase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Aspacytarabine (query alias: Aspacytarabine)
Modality / target	Small molecule drug; DNA polymerase; DNA polymerase inhibitors
Highest global status	Phase 2
Originator	BioSight Ltd.
Active developers	Groupe Francophone des Myélodysplasies, BioSight Ltd., GFM GmbH

The MCP disease footprint includes Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory acute myeloid leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03435848	Phase 2	Completed	66	Complete Remission
NCT04749355	Phase 2	Active, not recruiting	40	CR rate
NCT04827719	Phase 2	Completed	38	Overall hematological response

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: CR = 36.9 %

EFFICACY AND SAFETY OF ASPACYTARABINE (BST-236) AS A FIRST-LINE MONOTHERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD CHEMOTHERAPY

Phase 2; n=71; evaluation: not stated. Reported fields: CR = 35 %

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

Phase 2; n=46; evaluation: Positive. Reported fields: CR = 35 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Aspacytarabine addresses Acute Myeloid Leukemia, Myelodysplastic Syndromes, Refractory acute myeloid leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-07-27	Ayala Pharmaceuticals Announces Closing of Merger with Biosight	Phase 2	Financial terms not disclosed
2020-07-21	Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Compositions comprising aspacytarabine and additional compounds, and use thereof”. The milestone feed surfaced a patent-application signal described as “Crystalline forms of aspacytarabine”. The milestone feed surfaced a patent-application signal described as “Crystalline form of aspacytarabine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO